Skip to main content

Want a detailed portfolio tracker?

NRSN
NASDAQ
$0.70

NeuroSense Therapeutics Ltd (NRSN)

Neurosense Therapeutics Ltd (NRSN) is a clinical-stage biotechnology firm dedicated to innovating treatments for neurodegenerative diseases, with a particular emphasis on Parkinson's disease. The company is advancing a diverse pipeline of therapeutic candidates through pivotal clinical trials, addressing critical unmet needs in neurology. With a seasoned management team and strategic partnerships, Neurosense is poised to develop groundbreaking therapies that not only enhance patient outcomes but also bolster its competitive position in the biopharmaceutical sector.

This company is also listed under the following tickerNRSNW.

Website: https://www.neurosense-tx.com
Sector:
Healthcare
Industry:
Biotechnology
68 analysts
Buy
Target: $6.50 (+828.57%)

Market Cap

$23M

Free Cash Flow Yield

-32.81%

Beta (5Y)

0.57

Price Chart

Valuation
Market Cap$23M
P/B2.64
Profitability
EBITDA-$11M
EPS-$0.34
Financial Health
Free Cash Flow Yield-32.81%
Growth & Risk
EPS 5Y CAGR-17.43%
Beta (5Y)0.57
Sharpe Ratio-0.77